The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Weaker-than-expected revenues from prostate cancer med Pluvicto (lutetium vipivotide tetraxetan) held back Swiss cancer giant Novartis in its latest financial results statement. 31 January 2024
Chicago, USA-based biotech COUR Pharmaceuticals has raised $105 million in a series A financing round, co-led by Lumira Ventures and Alpha Wave Ventures. 31 January 2024
US gene therapy company Avrobio and privately-held biotech Tectonic Therapeutic today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction. 31 January 2024
US cell and gene therapy biotech 2seventy bio saw its share close up almost 15% at $4.01 yesterday, after it announced that it is transforming the company. 31 January 2024
Private company Defender Pharmaceuticals has had its submission for a new motion sickness treatment rejected by the US Food and Drug Administration. 31 January 2024
UK pharma major GSK today announced that its Omjjara (momelotinib) has now been granted Marketing Authorization (MA) in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA), following approval by the European Commission earlier this week. 31 January 2024
Japan has recently approved Dutch immunology specialist argenx’ (Euronext: ARGX) Vyvdura (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous (SC) injection for the treatment of adult patients with generalized myasthenia gravis (gMG), who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). 31 January 2024
A division of Indian generics drugmaker Glenmark Pharmaceuticals has agreed terms for a licensing deal with Chinese firms Alphamab Biopharmaceuticals and 3D Medicines. 30 January 2024
Vertex Pharmaceuticals today announced positive results from its Phase III program for the selective non-opioid selective NaV1.8 inhibitor V VX-548, in the treatment of moderate-to-severe acute pain. 30 January 2024
Indian drugmaker Orchid Pharma's antibiotic drug Exblifep (cefepime/enmetazobactam) has received approval from the European Medicines Agency (EMA), leading to a 20% surge in the company's stock. 30 January 2024
Danish biotech Ascendis Pharma today announced the formation and launch with Frazier Life Sciences of Eyconis Inc, a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. 30 January 2024
Britain’s medicines regulator has approved a novel antibiotic developed by Cidara Therapeutics, a biotechnology company based in San Diego, California. 30 January 2024
US precision genetic medicines firm Sarepta Therapeutics has announced positive data from Part B of the MOMENTUM study (Study SRP-5051-201), a global, Phase II, multi-ascending dose clinical trial of SRP-5051 (vesleteplirsen) that enrolled patients aged eight to 21 years. 30 January 2024
Two Californian firms, Gilead Sciences and Arcus Biosciences, have doubled down on their commitment to developing new therapies using the TIGIT pathway. 30 January 2024
Enterprise Therapeutics, a UK biopharma dedicated to the discovery and development of novel therapies for respiratory disease, has closed a £26 million ($33.1 million) Series B follow-on financing round, led by Panakes Partners. 30 January 2024
Following on from its recent approval of Hyqvia (immune globulin) in Europe, Japanese pharma major Takeda has picked up a US approval for another CIDP product. 30 January 2024
Industry observers are cautiously hoping that early 2024 signs indicate that the post-pandemic biotech fundraising slowdown might be coming to an end. 30 January 2024
Iceland-based developer of biosimilar medicines, Alvotech has announced positive top-line results from a pharmacokinetic (PK) study for AVT03, a biosimilar candidate to US biotech major Amgen’s Prolia and Xgeva, with both having the active ingredient denosumab at different dosages. 30 January 2024